ClinicalTrials.gg
Status unknownNCT05338957Updated Dec 1, 2022

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

A Phase 1/2 interventional study of MRG002+HX008 in Advanced Malignant Solid Tumors, sponsored by Shanghai Miracogen Inc.. Status unknown at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Shanghai Miracogen Inc. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.

02

Conditions studied

  • Advanced Malignant Solid Tumors

Keywords

  • MRG002
  • HX008
  • Antibody Drug Conjugate (ADC)
  • HER2
  • PD-1
  • Solid tumors
03

In context

Lead sponsor

Shanghai Miracogen Inc. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the form and follow the requirements specified in the protocol.
  2. Aged 18 to 75 (including 18 and 75), both genders.
  3. ≥ 12 weeks.
  4. Patients with histopathological or cytological confirmed -expressed advanced solid tumors, and with at least one according to the Response Criteria in Solid Tumors ( v1.1).
  5. The score of for performance status is 0 or 1.
  6. The toxicity of previous anti-tumor treatment has recovered to ≤ Grade 1 as defined by NCI-CTCAEv5.0.
  7. No severe cardiac dysfunction.
  8. Organ functions must meet the basic requirements.
  9. Cumulative dose of anthracycline ≤ 450 mg/m2 doxorubicin or its equivalent.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with chemotherapy, biological therapy, immunotherapy, radiotherapy, drugs, attenuated , immunomodulators, inhibitors/inducers, antibody-drug conjugates, etc.
  2. Treatment with or tumor vaccines within 60 days prior to the first dose.
  3. Treatment with systemic or other drugs within 14 days prior to the first dose or during the study period.
  4. History of severe cardiac disease.
  5. Poorly controlled hypertension and hyperglycemia.
  6. Presence of peripheral neuropathy ≥ Grade 2.
  7. History of moderate or severe dyspnea at rest due to advanced malignant tumor or its complications or severe primary pulmonary disease, or current need of continuous oxygen therapy, or current interstitial lung disease or pneumonia.
  8. Central nervous system .
  9. Received major surgery within 4 weeks prior to the first dose without complete recovery.
  10. History of to any component of MRG002 or HX008 or known history of hypersensitivity of ≥ Grade 3 to macromolecular protein products/monoclonal antibodies.
  11. Evidence of active infection.
  12. History of primary immunodeficiency or disease.
  13. Female patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate measures during the treatment and for 6 months after the last dose of study treatment.
  14. Previous history of other primary .
  15. Other conditions inappropriate for participation in this study, as deemed by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    MRG002+HX008

    MRG002 will be administrated via intravenous infusion at 1.8,,2.2, or 2.6 mg/kg , (if appropriate) once on Day 1 of every 3 weeks (21-day cycle), up to 24 months. HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day- cycle), up to 24 months.

    Drug: MRG002+HX008

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT) in each dose group

    DLT is defined as any of the treatment emergent adverse events (TEAE) as specified in the protocol that bear a definite, probable, or possible causal relationship to study drug administration within 28 days after the first dose.

    Time frame: Within 28 days after the first dose.

  2. Adverse events

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: After signing informed consent until 90 days after the last dose.

  3. Recommended Phase II Dose (RP2D)

    The dose level of MRG002 recommended for further clinical studies based on assessment of the safety, efficacy and PK data from this study.

    Time frame: Baseline to study completion (up to 24 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of subjects with CR and PR according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

  2. Duration of Response (DOR)

    DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  3. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects achieving CR, PR, and SD after treatment.

    Time frame: Baseline to study completion (up to 24 months)

  4. Progression Free Survival (PFS)

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  5. Time to Response (TTR)

    TTR is defined as the time from the start of treatment until the first occurrence of CR or PR by tumor assessment.

    Time frame: Baseline to study completion (up to 24 months)

  6. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  7. PK parameters: concentration-time curve

    Plot of drug concentration changing with time after drug administration.

    Time frame: Baseline to 90 days after the last dose.

  8. Immunogenicity (ADA)

    The proportion of patients with positive ADA results.

    Time frame: Baseline to 90 days after the last dose.

07

Study locations

5 of 5 sites recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Recruiting
    • Suxia Luo, Doctor · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan 410200, China
    Recruiting
    • Zhenyang Liu, Doctor · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong 250000, China
    Recruiting
    • Yuping Sun, Doctor · Contact
  • Shanghai Oriental Hospital
    Shanghai, Shanghai 200000, China
    Recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Ying yuan, Doctor · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Jun 2024, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2022
First posted
Apr 21, 2022
StartActual
Aug 5, 2022
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05338957
Lead sponsor
Shanghai Miracogen Inc.
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Aug 5, 2022
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Dec 1, 2022

Study contacts

Program Director
Contact
clinicaltrials@miracogen.com.cn
86-21-61637960
Jin Li, MD
principal investigator · Shanghai Oriental Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab vedotin · Pucotenlimab

Start the discussion